Compare XNET & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | FHTX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.5M | 360.8M |
| IPO Year | 2014 | 2020 |
| Metric | XNET | FHTX |
|---|---|---|
| Price | $5.66 | $5.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 281.1K | 163.7K |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8740.73 | N/A |
| EPS | ★ 20.16 | N/A |
| Revenue | ★ $401,918,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $40.91 |
| Revenue Next Year | N/A | $11.87 |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | ★ 27.19 | N/A |
| 52 Week Low | $2.64 | $2.95 |
| 52 Week High | $11.03 | $6.95 |
| Indicator | XNET | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 47.24 |
| Support Level | $5.55 | $5.11 |
| Resistance Level | $6.12 | $5.74 |
| Average True Range (ATR) | 0.32 | 0.37 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 22.19 | 32.58 |
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.